The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Sanofi
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
Other Relationship - Avantis Medical Systems
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec; Pierre Fabre
 
Mario Mandalà
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb; Novartis; Roche
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Ana Arance
No Relationships to Disclose
 
Erika Richtig
No Relationships to Disclose
 
Naoya Yamazaki
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical; Takara Bio
 
Caroline Robert
Consulting or Advisory Role - Amgen; Biothera; Bristol-Myers Squibb; CureVac; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; Incyte; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; Mologen; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Incyte; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; ImaginAb; Lutris; Merus; PACT Pharma; Rgenix; Tango Therapeutics
Honoraria - Amgen; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
 
Keith Flaherty
Leadership - Adaptimmune; Aeglea Biotherapeutics; Amgen; Apricity Health; Asana Biosciences; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Fount Therapeutics; Monopteros Therapeutics; Neon Therapeutics; Oncoceutics; PIC Therapeutics; Sanofi; Shattuck Labs; Strata Oncology; Tolero Pharmaceuticals; Tvardi Therapeutics; Vibliome Therapeutics; Vivid Biosciences; X4 Pharma; Xcures
Stock and Other Ownership Interests - Adaptimmune; Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; Fount Therapeutics; Monopteros Therapeutics; Oncoceutics; PIC Therapeutics; Strata Oncology; Tvardi Therapeutics; Vibliome Therapeutics; Vivid Biosciences; X4 Pharma; Xcures
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Apricity Health; Asana Biosciences; Boston Biomedical; Bristol-Myers Squibb; Debiopharm Group; FOGPharma; Fount Therapeutics; Genentech; Merck; Monopteros Therapeutics; Neon Therapeutics; Novartis; Oncoceutics; PIC Therapeutics; Pierre Fabre; Sanofi; Shattuck Labs; Takeda; Tolero Pharmaceuticals; Tvardi Therapeutics; Verastem; Vibliome Therapeutics; X4 Pharma; Xcures
Research Funding - Novartis; Sanofi
 
Neha Pakhle
Employment - Novartis
Travel, Accommodations, Expenses - Novartis
 
Aisha Masood
Employment - Novartis
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novartis
 
Eduard Gasal
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)